UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

Under the Securities Exchange Act of 1934

For the Month of ~~February~~March 2026

001-36203

(Commission File Number)

CAN-FITE BIOPHARMA LTD.

(Exact name of Registrant as specified in its charter)

26 Ben Gurion Street

Ramat Gan 5257346 Israel

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

~~The~~On ~~first~~March ~~nine~~3, ~~paragraphs~~2026, ofCan-Fite ~~the~~BioPharma ~~press~~Ltd. ~~release~~(the ~~attached~~“Company”) ~~hereto~~convened asa ~~Exhibit~~Special ~~99.1,~~General ~~other~~Meeting ~~than~~of Shareholders (the ~~eighth~~“Meeting”). ~~paragraph~~However, ~~are hereby incorporated by reference into~~ the ~~registrant’s~~Meeting ~~Registration~~was adjourned ~~Statements~~for onone ~~Form~~week ~~S-8~~to ~~(File~~the ~~Nos.~~same ~~333-227753~~day, ~~333-271384~~ ~~and~~time ~~333-278525)~~ and ~~Form~~place ~~F-3~~due ~~(File~~to ~~Nos~~lack of quorum. ~~333-236064~~Accordingly, ~~333-274316,~~ ~~333-262055, 333-276000~~the ~~and~~Meeting ~~333-281872), to~~will be areconvened ~~part~~on ~~thereof~~Tuesday, ~~from~~March ~~the~~10, 2026 ~~date~~at on3:00 ~~which~~p.m., ~~this~~Israel ~~report~~time isat ~~submitted, to~~ the ~~extent~~Company’s ~~not~~offices ~~superseded~~located byat ~~documents~~26 orBen ~~reports~~Gurion ~~subsequently filed~~Street, orRamat ~~furnished~~Gan, Israel.

On February 17, 2026, Can-Fite BioPharma Ltd. issued a press release entitled “Can-Fite Announces Scientific Breakthrough Publication Demonstrating Anti-Obesity Effect of Namodenoson”. A copy of this press release is furnished herewith as Exhibit 99.1.

Exhibit Index

Exhibit No.		Description
99.1		Press Release dated February 17, 2026

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Date: February 17, 2026	By:	/s/ Motti Farbstein
Date: March 3, 2026	By:	/s/ Motti Farbstein
		Motti Farbstein
		Chief Executive Officer and Chief Financial Officer

Filing Compare · Can-Fite BioPharma Ltd.